Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting

Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and c...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2024-04, Vol.63 (4), p.503-511
Main Authors: Daudén, Esteban, Escario, Elena, Martos-Cabrera, Luisa, Armesto, Susana, Herrera-Acosta, Enrique, Vidal, David, Vilarrasa, Eva, Rivera, Raquel, de la Cueva, Pablo, Martorell, Antonio, Ballesca, Ferran, Belinchón, Isabel, Carretero, Gregorio, Rodríguez, Lourdes, Romero-Maté, Alberto, Pujol-Montcusí, J, Salgado, Laura, Sahuquillo-Torralba, Antonio, Coto-Segura, Pablo, Baniandrés, Ofelia, Feltes, R, Riera-Monroig, Josep, Garrido, Jesus, Llamas-Velasco, Mar
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Cohort analysis
Cohort Studies
Drug dosages
Drug Tapering
Humans
Psoriasis
Psoriasis - chemically induced
Psoriasis - drug therapy
Retrospective Studies
Safety
Severity of Illness Index
Skin diseases
Survival
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biological therapy dose modification is a common practice in the long-term treatment of plaque psoriasis. The objective of the study was to determine prevalence, characteristics of patients, effectiveness, treatment survival of secukinumab dose reduction (SEC-DR) strategy and assess its safety and cost implications. A retrospective, observational, multicenter cohort study was conducted in patients with plaque psoriasis treated with secukinumab and up to 2 years of follow-up. In 63/347 patients with an initial standard dose regimen, SEC-DR was tried at any moment in 18.2% of them after sustained response. In 51 patients, the interval between administrations was increased while in 12 patients, monthly dose was reduced to 150 mg. Successful SEC-DR was achieved in 77.8% of the patients, with sustained PASI response to the end of the study. Survival of secukinumab treatment and safety profile were not compromised by DR. The use of DR saved 33% of the cost, including failures in which standard treatment was resumed. The proper of the study designed and the arbitrary definition of "DR success." Off-label SEC-DR strategy was used in patients with sustained response to standard dose regimen; this strategy showed long-term efficacy without compromising treatment survival or worsening the safety profile while also being cost saving.
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.16915